grepcent public filings, reorganized for comparison

InnovAge Holding Corp. (INNV)

CIK: 0001834376. SIC: 8000 Services-Health Services. Latest 10-K as of: 2026-09-09.

SIC breadcrumb: Services > SIC Major Group 80 > SIC 8000 Services-Health Services

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1834376. Latest filing source: 0001834376-26-000049.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2026 · period end 2026-06-30 · filed 2026-09-09 · accession 0001834376-26-000049 · source: SEC companyfacts

Revenue
989,707,000 USD verified
Net income
-2,537,000 USD verified
Assets
557,393,000 USD verified
Free cash flow
50,405,000 USD computed
Net margin
-0.26% computed
Operating margin
0.26% computed
Revenue YoY
+15.93% computed
ROE
-1.08% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

INNV ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 8000; per-ratio N printed.INNV ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 8000; per-ratio N printed.RatioINNVPeer medianPercentileNNet margin-0.3%0.9%3310Operating margin0.3%0.8%4410Revenue growth15.9%22.1%2210FCF margin5.1%5.8%438ROE-1.1%1.9%3310ROA-0.5%1.1%3310Liabilities / equity1.230.678910Current ratio1.051.951110

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 8000 Services-Health Services, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue989,707,000USD20262026-09-09
Net income-2,537,000USD20262026-09-09
Assets557,393,000USD20262026-09-09

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-09-09. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001834376.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric20192020202120222023202420252026
Revenue567,192,000637,800,000698,640,000688,087,000763,855,000853,699,000989,707,000
Net income26,278,000-43,986,000-6,521,000-40,673,000-21,338,000-30,313,000-2,537,000
Operating income50,933,000-12,337,000-4,406,000-49,395,000-23,180,000-29,761,0002,618,000
Gross profit135,372,000101,288,000132,064,000153,639,000227,764,000
Diluted EPS0.19-0.36-0.05-0.30-0.16-0.22-0.02
Operating cash flow43,828,000-7,548,00027,302,00020,236,000-36,898,00032,866,00064,714,000
Capital expenditures11,844,00017,541,00038,238,00023,354,0007,914,0006,263,00014,309,000
Assets409,634,000531,752,000555,596,000567,358,000547,661,000526,851,000557,393,000
Liabilities301,884,000173,787,000201,852,000252,558,000247,853,000263,943,000288,617,000
Stockholders' equity101,015,000334,559,000332,364,000296,299,000269,261,000234,968,000235,603,000
Cash and cash equivalents9,000,000112,904,000201,466,000184,429,000127,249,00056,946,00064,129,00097,891,000
Free cash flow31,984,000-25,089,000-10,936,000-3,118,000-44,812,00026,603,00050,405,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric20192020202120222023202420252026
Net margin4.63%-6.90%-0.93%-5.91%-2.79%-3.55%-0.26%
Operating margin8.98%-1.93%-0.63%-7.18%-3.03%-3.49%0.26%
Return on equity26.01%-13.15%-1.96%-13.73%-7.92%-12.90%-1.08%
Return on assets6.41%-8.27%-1.17%-7.17%-3.90%-5.75%-0.46%
Liabilities / equity2.990.520.610.850.921.121.23
Current ratio2.183.192.291.451.251.071.05

Industry Peer Context

Each number-line places INNV against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

INNV Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.INNV Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.10 SIC peersMin -56.6%Median 0.9%Max 21.0%INNV -0.3%

Operating margin peer context

INNV Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.INNV Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.10 SIC peersMin -55.3%Median 0.8%Max 11.1%INNV 0.3%

ROE peer context

INNV ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.INNV ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.10 SIC peersMin -126.7%Median 1.9%Max 14.8%INNV -1.1%

ROA peer context

INNV ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.INNV ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8000; peer count 10.10 SIC peersMin -84.0%Median 1.1%Max 12.7%INNV -0.5%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

INNV FY2026 income statement bridge from reported figures.INNV FY2026 income statement bridge from reported figures.INNV income bridgeFY2026: revenue to net incomeSource: SEC companyfacts FY2026.Income statement bridgeReported amount-$250.0M$0.0B$1.0B$989.7MRevenue-$761.9MCost$227.8MGross-$225.1MOpEx$2.6MOperating-$5.2MOther/tax-$2.5MNet income

Figure provenance: SEC companyfacts FY 2026. Revenue: accession 0001834376-26-000049; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001834376-26-000049; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001834376-26-000049; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001834376-26-000049; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

INNV FY2026 free cash flow bridge from reported figures.INNV FY2026 free cash flow bridge from reported figures.INNV free cash flow bridgeFY2026: operating cash flow less capital expendituresSource: SEC companyfacts FY2026.Free cash flow bridgeReported amount$0.0B$125.0M$250.0M$64.7MOperating cash flow-$14.3MCapex$50.4MFree cash flow

Figure provenance: SEC companyfacts FY 2026. Operating cash flow: accession 0001834376-26-000049; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001834376-26-000049; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001834376-26-000049; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

INNV revenue, last 5 periods. Source: SEC companyfacts FY2026.INNV revenue, last 5 periods. Source: SEC companyfacts FY2026.INNV RevenueLatest point: FY2026 = $989.7MSource: SEC companyfacts FY2026.Fiscal yearReported revenue$0.0B$500.0M$1.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

INNV net income, last 5 periods. Source: SEC companyfacts FY2026.INNV net income, last 5 periods. Source: SEC companyfacts FY2026.INNV Net incomeLatest point: FY2026 = -$2.5MSource: SEC companyfacts FY2026.Fiscal yearNet income-$250.0M-$125.0M$0.0BFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

INNV operating income, last 5 periods. Source: SEC companyfacts FY2026.INNV operating income, last 5 periods. Source: SEC companyfacts FY2026.INNV Operating incomeLatest point: FY2026 = $2.6MSource: SEC companyfacts FY2026.Fiscal yearOperating income-$250.0M$0.0B$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

INNV gross profit, last 5 periods. Source: SEC companyfacts FY2026.INNV gross profit, last 5 periods. Source: SEC companyfacts FY2026.INNV Gross profitLatest point: FY2026 = $227.8MSource: SEC companyfacts FY2026.Fiscal yearGross profit$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

INNV diluted eps, last 5 periods. Source: SEC companyfacts FY2026.INNV diluted eps, last 5 periods. Source: SEC companyfacts FY2026.INNV Diluted EPSLatest point: FY2026 = -$0.02/shareSource: SEC companyfacts FY2026.Fiscal yearDiluted EPS (USD/share)-$0.50/share-$0.25/share$0.00/shareFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

INNV operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.INNV operating cash flow, last 5 periods. Source: SEC companyfacts FY2026.INNV Operating cash flowLatest point: FY2026 = $64.7MSource: SEC companyfacts FY2026.Fiscal yearOperating cash flow-$250.0M$0.0B$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

INNV capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.INNV capital expenditures, last 5 periods. Source: SEC companyfacts FY2026.INNV Capital expendituresLatest point: FY2026 = $14.3MSource: SEC companyfacts FY2026.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

INNV assets, last 5 periods. Source: SEC companyfacts FY2026.INNV assets, last 5 periods. Source: SEC companyfacts FY2026.INNV AssetsLatest point: FY2026 = $557.4MSource: SEC companyfacts FY2026.Fiscal yearAssets$0.0B$375.0M$750.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: Assets. Source concepts: us-gaap:Assets.

INNV liabilities, last 5 periods. Source: SEC companyfacts FY2026.INNV liabilities, last 5 periods. Source: SEC companyfacts FY2026.INNV LiabilitiesLatest point: FY2026 = $288.6MSource: SEC companyfacts FY2026.Fiscal yearLiabilities$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

INNV stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.INNV stockholders' equity, last 5 periods. Source: SEC companyfacts FY2026.INNV Stockholders' equityLatest point: FY2026 = $235.6MSource: SEC companyfacts FY2026.Fiscal yearStockholders' equity$0.0B$250.0M$500.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

INNV cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.INNV cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2026.INNV Cash and cash equivalentsLatest point: FY2026 = $97.9MSource: SEC companyfacts FY2026.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

INNV free cash flow, last 5 periods. Source: SEC companyfacts FY2026.INNV free cash flow, last 5 periods. Source: SEC companyfacts FY2026.INNV Free cash flowLatest point: FY2026 = $50.4MSource: SEC companyfacts FY2026.Fiscal yearFree cash flow-$250.0M$0.0B$250.0MFY2022FY2023FY2024FY2025FY2026

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-09-09. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001834376.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2023-Q12022-09-30-0.10reported discrete quarter
2023-Q22022-12-31-0.07reported discrete quarter
2023-Q32023-03-31-0.05reported discrete quarter
2024-Q12023-09-30182,485,000-10,304,000-0.08reported discrete quarter
2024-Q22023-12-31188,898,000-3,447,000-0.03reported discrete quarter
2024-Q32024-03-31193,071,000-5,887,000-0.04reported discrete quarter
2024-Q42024-06-30199,401,000-1,700,000derived Q4 = FY annual - nine-month YTD
2025-Q12024-09-30205,142,000-4,929,000-0.04reported discrete quarter
2025-Q22024-12-31208,999,000-13,221,000-0.10reported discrete quarter
2025-Q32025-03-31218,142,000-11,378,000-0.08reported discrete quarter
2025-Q42025-06-30221,417,000-785,000derived Q4 = FY annual - nine-month YTD
2026-Q12025-09-30236,105,0008,019,0000.06reported discrete quarter
2026-Q22025-12-31239,708,00010,618,0000.08reported discrete quarter
2026-Q32026-03-31251,943,000-29,461,000-0.22reported discrete quarter
2026-Q42026-06-30261,951,0008,287,000derived Q4 = FY annual - nine-month YTD

Quarterly Charts

INNV quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.INNV quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q4.INNV Quarterly RevenueLatest point: 2026-Q4 = $262.0MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Revenue$0.0B$250.0M$500.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

INNV quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.INNV quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q4.INNV Quarterly Net incomeLatest point: 2026-Q4 = $8.3MSource: SEC companyfacts 2026-Q4.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q22026-Q32026-Q4

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001834376-26-000049; filed 2026-09-09. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

INNV quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.INNV quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q3.INNV Quarterly Diluted EPSLatest point: 2026-Q3 = -$0.22/shareSource: SEC companyfacts 2026-Q3.Fiscal quarterQuarterly Diluted EPS (USD/share)-$0.50/share$0.00/share$0.50/share2023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q22026-Q3

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001834376-26-000022; filed 2026-05-08. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read INNV's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read INNV's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001834376-26-000022.

Extracted from a substantive MD&A body after the formal Item 2 span was a TOC or reference stub. Published MD&A gate trimmed front/tail over-capture. Confidence: high. Filing date: 2026-05-08. Report date: 2026-03-31.

Overview

InnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. As of March 31, 2026, the Company served approximately 8,050 PACE participants, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia.

Trends and Uncertainties Affecting the Company

Increased cost of care and external provider costs. We anticipate increased cost of care from our third-party service providers in an effort to offset their heightened expenses resulting, in part, from budget pressures due to the OBBBA, budget cuts to providers from state Medicaid programs, and possible increases in cost of medical and other supplies used in order to provide healthcare services. While we did not experience a material increase to our cost of care through the third quarter of fiscal year 2026, we continue to monitor the situation. We believe that our clinical value initiatives and operational value initiatives, which continue to be executed, may assist us in offsetting any increased cost of care anticipated for the last quarter of fiscal year 2026.

Labor market and access to supportive housing facilities. The healthcare sector continues to experience workforce shortages, particularly in geriatrics, primary care and direct care roles, as well as a complex set of challenges in hiring additional professionals, which continued through the third quarter of fiscal year 2026. Competition from health systems and home health providers for nurses, drivers and caregivers, in addition to the systemic challenges related to workforce training and the pipeline of qualified professionals, has remained challenging for the Company’s ability to recruit and retain staff. These labor market pressures have increased wage and benefit costs, and have also affected our staffing ability which could impact our enrollment capacity and services. To mitigate these challenges, we continue to review and implement targeted compensation in line with the markets in which we operate and focused retention programs for critical roles, along with operational measures to help improve productivity and continue reducing reliance on agency staffing. Partially as a result of increased competition and other market trends, there was an increase in the cost of care for the third quarter of fiscal year 2026 compared to the comparable period for fiscal year 2025, as discussed in "Results of Operations" below.

In addition, a shortage of clinicians combined with an aging population creates increased demand on the limited number of existing residential facilities. As a result, the access of our participants to such facilities is uncertain, as such facilities may prioritize private payors or may be unable to accept participants at pre-determined rates. If we are unable to access residential facilities, we could be unable to continue providing PACE services to participants who require such facilities.

Census and capitation revenue. The delays and increased gaps in eligibility both for new enrollments and Medicaid redetermination applications that we experienced during fiscal years 2025 and 2024 due to processing delays and other enrollment and redetermination procedures that vary by State and county continued into the third quarter of fiscal year 2026, though to a lesser degree than experienced at the end of fiscal year 2025. While processing delays generally reduced in measure during the first three quarters of fiscal year 2026, it is possible that these delays could persist or be exacerbated due to potential future impacts of the OBBBA. This has not had a material effect on the Company’s financial statements or operations; however, we continue to monitor the situation.

Medicaid Spending and Rates. Among other things, the OBBBA has constrained states' use of provider taxes to finance Medicaid programs and some states have mandated changes in order to reduce Medicaid spending. Consequent state budgetary pressures may lead to (i) reductions in state workforce which may include those responsible for overseeing

30

Table of Contents

PACE, possibly causing delays in eligibility determinations and discharge of other state responsibilities; (ii) reduction or removal of optional Medicaid services from the PACE benefit package; and (iii) pressure on Medicaid capitation rates. In Colorado, where we serve the largest cohort of our PACE census, we anticipate reduced Medicaid premium rate increases for the fiscal year beginning July 1, 2026. We also expect to face Medicaid reimbursement wage pressures from other states, such as California, which release rates effective January 1, 2027, and which could impact the latter half of our fiscal year. While we continue to monitor the full effects of the OBBBA on the Company we expect the rate pressures to impact the Company's margins in fiscal 2027.

California Moratorium. Effective November 20, 2025, the California Department of Health Care Services (DHCS) paused PACE applications for all PACE organizations for a minimum of two years, or until otherwise notified. The pause does not apply to the Downey and Bakersfield center applications, which are considered to be in the review process. The pause, however, would impact the opening and/or acquisition of other de novo centers in the state of California.

For additional information on the various risks posed by macroeconomic events, regulation, and employee matters, please see the section entitled “Risk Factors” included in Part I, Item 1A of our 2025 10-K.

Key Factors Affecting Our Performance

Our historical financial performance has been, and we expect our financial performance in the future to be, driven by the following factors:

•Our participants. We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we believe we manage a higher acuity population, with an average risk adjustment factor (“RAF”) score of 2.52 based on InnovAge data as of March 31, 2026; and (ii) we have Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive PMPM payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant. We continue to strengthen our encounter data submission process so that our revenue more accurately reflects the acuity of the populations we serve.

•Our ability to grow enrollment and capacity within existing centers. We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including competition, costs and sanctions issued by regulators or suspensions of State attestations required to open new de novo centers.

•Our ability to maintain high participant satisfaction and retention. Our comprehensive individualized care model and frequency of interaction with participants generate high levels of participant satisfaction. Our average participant tenure was 3.2 years as of March 31, 2026, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 7.0% annually over the last three fiscal years.

•Effectively managing the cost of care for our participants. We receive capitated payments to manage the totality of a participant’s medical care across all settings. The risk pool of our population is highly acute. Various factors, including increased salaries, wages and benefits, increased staffing, annual increases in assisted living and nursing facility unit cost and general medical inflation have affected our external provider costs and cost of care, excluding depreciation and amortization, which represented approximately 77% of our revenue in the nine months ended March 31, 2026.

•Center-level Contribution Margin. The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. As we serve more participants in existing

31

Table of Contents

centers, we anticipate being able to leverage our fixed cost base at those centers and increase the value of a center to our business over time.

•Our ability to expand via de novo centers within existing and new markets. Several factors can affect our ability to open de novo centers, including actions by local and state regulators, such as the moratorium issued in California by DHCS and any sanctions issued, legal, community or other obstacles in the construction or opening of such centers.

In response to an audit to our Sacramento center and a medical review of our San Bernardino center, which have been previously disclosed, DHCS suspended its attestations in support of the planned de novo centers in Downey and Bakersfield, California. CMS has closed its process and DHCS's process is ongoing. On December 23, 2025, we received a formal Corrective Action Plan (CAP) from DHCS to remediate findings resulting from the San Bernardino medical review. We are working closely with the State to fulfill the obligations of the CAP. While the planned California de novo centers are precluded from opening at this time, DHCS notified us that it would consider restoring the State Attestations upon our successful remediation of the deficiencies raised in our Sacramento center and its completion of the medical review, including the resultant remediation, in our San Bernardino center.

•Execute tuck-in acquisitions, strategic transactions and partnerships. Since fiscal year 2019, we have acquired and integrated four PACE organizations for a total of eight operational centers (excluding the PACE center in Bakersfield, California, which is not yet operational). These acquisitions represent expansion of our InnovAge Platform into one new state and five new markets. By bringing acquired organizations under the InnovAge Platform, we anticipate increased revenue growth and operational efficiency and care delivery post-integration. We also have pursued and intend to continue pursuing additional relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geographies, such as the joint ventures with Orlando Health and Tampa General Hospital relating to our Orlando PACE center and our Tampa PACE center, respectively. In fiscal year 2025, we acquired certain pharmacy assets from Tabula Rasa HealthCare Group, Inc. (“TRHC”), with the goal of supporting our growth and improving pharmacy cost-management.

•Our ability to maintain high quality of regulatory compliance. The Company's priority is to continue to maintain high quality of regulatory compliance in all its centers.

•Contracting with government payors. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payor but also as a key partner in our efforts to e

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001834376-26-000049. The complete FY 2026 MD&A is published at /company/INNV/mda/fy2026/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high. Filing date: 2026-09-09. Report date: 2026-06-30.

Item 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this Annual Report. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Our historical results are not necessarily indicative of the results that may occur in the future and actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and in the sections entitled “Risk Factors” and “Cautionary Note About Forward-Looking Statements” included in this Annual Report.

Overview

General

InnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. The Company served approximately 8,230 PACE participants as of June 30, 2026, making it the largest PACE provider in the U.S. based upon participants served, and operates 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.

At the beginning of fiscal year 2027, to increase operational efficiency, we began the process of converting two legacy PACE centers to alternate care setting (“ACS”) centers in Pennsylvania. Once the process is complete, which we expect to be during the second fiscal quarter, these ACS centers will provide our participants with flexibility to participate in activities and receive certain services.

Operations

InnovAge’s programs are designed to allow frail seniors to live life on their terms by aging in place, in their own homes and communities, for as long as safely possible. Through our Program of All-Inclusive Care for the Elderly (“PACE”), we fulfill a broad range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE.

We are the leading healthcare delivery platform by number of participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Our programs are designed to directly address two of the most pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of our participant-centered care delivery approach is to improve the quality of care our participants receive, while keeping them in their homes for as long as safely possible and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. Our participant-centered approach is led by our Interdisciplinary Care Teams (“IDTs”), who oversee all aspects of each participant’s unique care plan and function as the core group of care providers to our participants. We directly manage and are responsible for all healthcare needs and associated costs for our participants, including housing costs, where applicable. We directly contract with government payors, such as Medicare and Medicaid, and do not rely on third-party administrative organizations or health plans. We believe our model aligns with how healthcare is evolving, namely (i) the shift toward value-based care, in which coordinated, outcomes-driven, quality care is delivered while seeking to reduce unnecessary spend, (ii) reducing excessive administrative costs by contracting directly with the government, (iii) focusing on the patient experience and (iv) addressing social determinants of health.

Trends and Uncertainties Affecting the Company

Increased cost of care and external provider costs. We anticipate increased cost of care from our third-party service providers in an effort to offset their heightened expenses resulting, in part, from budget pressures due to the Reconciliation Act, budget cuts to providers from state Medicaid programs, as well as possible increases in other costs in order to provide healthcare services. While we did not experience a material increase to our cost of care through fiscal year 2026, we continue to monitor the situation. We believe that our clinical value initiatives and operational value initiatives, which continue to be executed, may assist us in reducing unnecessary utilization and offsetting the increased cost of care anticipated for fiscal year 2027.

47

Table of Contents

Labor market. Throughout fiscal year 2026, the healthcare sector continued to experience workforce shortages, particularly in geriatrics, primary care and direct care roles, as well as a complex set of challenges in hiring additional professionals. Competition from health systems and home health providers, drivers and caregivers, has remained challenging for the Company’s ability to recruit and retain staff. Labor market pressures and competition continues to impact wage and benefit costs for our direct care providers and have also affected our staffing ability, which could impact our enrollment capacity. To mitigate these challenges, we continue to review our compensation and benefits to align with the markets in which we operate and focus our retention programs on critical roles and our operational measures to help improve productivity and continue reducing reliance on agency staffing. Partially as a result of increased competition and other market trends, there was an increase in the cost of care for fiscal year 2026 compared to fiscal year 2025, as discussed in "Results of Operations" below.

Census and capitation revenue. We continue to monitor the delays and increased gaps in eligibility, both for new enrollments and Medicaid redetermination applications during fiscal year 2026. Such delays and eligibility gaps stem from issues with state enrollment and redetermination processes, which vary by state and county. While processing delays abated modestly during fiscal year 2026, it is possible these delays could persist or increase due to potential impacts of the Reconciliation Act. The foregoing has not yet had a material effect on the Company’s financial statements or operations; however, we continue to monitor the situation.

Medicaid Spending. Among other things, the Reconciliation Act has constrained states’ use of provider taxes to finance Medicaid programs and some states have mandated changes in order to reduce Medicaid spending. Consequent state budgetary pressures may lead to (i) reductions in state workforce, which may include those responsible for overseeing PACE, possibly causing delays in eligibility determinations and discharge of other state responsibilities; (ii) reduction or removal of optional Medicaid services from the PACE benefit package; and (iii) pressure on Medicaid capitation rates. In Colorado, where we serve the largest cohort of our PACE census, we anticipate a decrease in Medicaid premium rates which will be retroactive for the fiscal year beginning July 1, 2026. We also expect to face Medicaid reimbursement wage pressures from other states that release rates effective January 1, 2027, such as California, which could impact the latter half of our fiscal year. We expect the rate pressures to impact the Company’s margins in fiscal year 2027 and continue to monitor the full effects of the Reconciliation Act on the Company.

California Moratorium. Effective November 20, 2025, the California Department of Health Care Services (DHCS) paused PACE applications for all new PACE centers for a minimum of two years, or until otherwise notified. The pause does not apply to the ongoing Bakersfield center application, the review of which may resume following remediation of the deficiencies raised in our Sacramento and San Bernardino centers and the completion of the San Bernardino medical review. The pause, however, would impact the opening of other de novo centers in the state of California.

For additional information on the various risks posed by macroeconomic events, regulation, and employee matters, please see the section entitled “Risk Factors” included in Part I, Item 1A of this Annual Report.

Key Factors Affecting Our Performance

Our historical financial performance has been, and we expect our financial performance in the future to be, driven by the following factors:

•Our participants. We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we believe we manage a higher acuity population, with an average RAF score of 2.48 based on InnovAge data as of June 30, 2026; and (ii) we have Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive PMPM payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant. We continue to strengthen our encounter data submission process so that our revenue more accurately reflects the acuity of the populations we serve.

48

Table of Contents

•Our ability to grow enrollment and capacity within existing centers. We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including competition, costs and regulatory compliance.

•Our ability to maintain high participant satisfaction and retention. Our comprehensive individualized care model and frequency of interaction with participants generates high levels of participant satisfaction. We achieved an I-SAT NPS score of 52 for fiscal year 2026 and average participant tenure of 3.1 years as of June 30, 2026, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 6.5% annually over the last three fiscal years.

•Effectively managing. We receive capitated payments to manage the totality of a participant’s medical care across all settings. The risk pool of our population is highly acute. Various factors, including increased salaries, wages and benefits, increased staffing, annual increases in assisted living and nursing facility unit cost and general medical inflation, have affected our external provider costs and cost of care, excluding depreciation and amortization, which represented approximately 77% of our revenue in the year ended June 30, 2026.

•Center-level Contribution Margin. The Company’s management uses Center-level Contribution

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for INNV

Indicators mapped to this company's SIC classification (industry 8000 Services-Health Services) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/INNV.md · JSON record: /company/INNV.json · verified financials: JSON / CSV · concise section index: /llms.txt